Deciphera Pharmaceuticals LLC Analysis
Deciphera Pharmaceuticals LLC is undervalued with Real Value of 0.0 and Hype Value of 0.0. The main objective of Deciphera Pharmaceuticals delisted stock analysis is to determine its intrinsic value, which is an estimate of what Deciphera Pharmaceuticals LLC is worth, separate from its market price. There are two main types of Deciphera Pharmaceuticals' stock analysis: fundamental analysis and technical analysis.
The Deciphera Pharmaceuticals stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Deciphera Pharmaceuticals' ongoing operational relationships across important fundamental and technical indicators.
Deciphera |
Deciphera Stock Analysis Notes
About 28.0% of the company shares are held by company insiders. The company recorded a loss per share of 2.21. Deciphera Pharmaceuticals had not issued any dividends in recent years. Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts. Deciphera Pharmaceuticals operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 280 people. To learn more about Deciphera Pharmaceuticals LLC call Steven Hoerter at 781 209 6400 or check out https://www.deciphera.com.Deciphera Pharmaceuticals Investment Alerts
| Deciphera Pharmaceuticals is not yet fully synchronised with the market data | |
| Deciphera Pharmaceuticals has some characteristics of a very speculative penny stock | |
| Deciphera Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 163.36 M. Net Loss for the year was (194.94 M) with loss before overhead, payroll, taxes, and interest of (62.55 M). | |
| Deciphera Pharmaceuticals LLC currently holds about 383.85 M in cash with (146.7 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.74. | |
| Roughly 72.0% of the company shares are held by institutions such as insurance companies |
Deciphera Pharmaceuticals Upcoming and Recent Events
Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Deciphera Pharmaceuticals previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 6th of February 2024 Upcoming Quarterly Report | View | |
| 1st of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 6th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Deciphera Market Capitalization
The company currently falls under 'Mid-Cap' category with a current market capitalization of 2.21 B.Deciphera Profitablity
The company has Profit Margin (PM) of (1.09) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (1.09) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $1.09.Deciphera Pharmaceuticals Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Deciphera Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Deciphera Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Deciphera Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Deciphera Pharmaceuticals Outstanding Bonds
Deciphera Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Deciphera Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Deciphera bonds can be classified according to their maturity, which is the date when Deciphera Pharmaceuticals LLC has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View |
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding Deciphera Pharmaceuticals to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Earnings Calls Now
Earnings CallsCheck upcoming earnings announcements updated hourly across public exchanges |
| All Next | Launch Module |
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
Other Consideration for investing in Deciphera Stock
If you are still planning to invest in Deciphera Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Deciphera Pharmaceuticals' history and understand the potential risks before investing.
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal |